71 results about "Strong binding" patented technology

The invention provides a GPRC5D single-domain antibody B11, and the GPRC5D single-domain antibody B11 has relatively strong binding activity and reaction specificity on GPRC5D. The invention provides an amino acid sequence of a single-domain antibody, an antibody derivative, a biological material and application thereof. The single-domain antibody provided by the invention can be used for constructing a chimeric antigen receptor T cell, and the chimeric antigen receptor T cell has stronger killing power on a target cell.

The invention is suitable for the technical field of biological medicine and nuclear medicine, and provides a PD-L1 targeting compound, a radioactive tracer agent and a preparation method and application of the PD-L1 targeting compound and the radioactive tracer agent. The radioactive tracer provided by the invention has strong binding force with PD-L1, can accurately locate PD-L1 in vivo, has excellent in-vivo targeting performance, and can achieve the purpose of tumor molecular imaging through nuclear medicine imaging; meanwhile, noninvasive visualization of PD-L1 expression is achieved, non-invasive tumor diagnosis can be effectively completed through small animal PET / CT verification, and the clinical application prospect is wide; in addition, the PD-L1 targeting compound and the radioactive tracer derived from the PD-L1 targeting compound further have the advantages of being simple in preparation process, low in cost, high in specificity, good in in-vivo and in-vitro stability, long in imaging period, easy to clinically convert and the like, and the comprehensive performance is outstanding.

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

The invention discloses a hybridoma cell strain secreting an anti-CD4 antibody, the antibody and application of the hybridoma cell strain in detection of CD4 of cattle and sheep, and belongs to the technical field of biology. The hybridoma cell strain is 3F9 and is preserved in the China Center for Type Culture Collection on June 13, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2025183. The anti-CD4 antibody 3F9 secreted by the hybridoma cell strain provided by the invention has the advantages of high titer and strong binding affinity with natural antigens, and can be used for detecting natural cattle CD4 and sheep CD4 molecules.

This invention belongs to the field of antigen recognition technology, specifically relating to an antibody or its antigen-binding fragment that targets and recognizes mCD155, and its applications. The antibody targeting and recognizing mCD155 includes sequences as shown in SEQ ID NO:8 and SEQ ID NO:16 or as shown in SEQ ID NO:24 and SEQ ID NO:32; it has a strong binding affinity to the mCD155-his protein; and CAR-T cells constructed based on this antibody exhibit excellent killing (apoptotic) activity against mCD155-mediated tumors.

Provided in the present invention are a solid form of a cyclic amine derivative, a preparation method therefor, and a pharmaceutical composition, specifically relating to a solid form of a compound of formula I or a salt thereof, a preparation method therefor, and a pharmaceutical composition. The compound of formula I or the salt thereof provided by the present invention has strong binding ability to apo(a) and high stability, and can be better used in clinical practice.

The utility model discloses a multi-layer graphene heat-conducting sheet with strong binding force and rebound resilience, which comprises a plurality of graphene films which are punched by a laser and irradiated by an ultraviolet lamp for 1-2 minutes; coating the surface of the first graphene film with a first silica gel layer; placing a second graphene film on the first silica gel layer; enabling a part of the first silica gel layer to permeate into the holes of the first graphene film and the second graphene film; repeating the stacking to form a transverse graphene film and silica gel composite material block; cutting along the direction of the stacking thickness to form a plurality of stacked slices; the upper end face and the lower end face are subjected to degumming operation, graphene fiber filling operation is carried out after a hollow part is formed, all the graphene films can be connected with one another, and the multi-layer graphene heat-conducting sheet is high in binding force and rebound resilience. Therefore, the graphene has good bonding performance, can bear high compression rate without cracking, and fundamentally solves the cracking problem of the conventional graphene heat-conducting sheet.

The present invention provides a starch-fatty alcohol complex and a preparation method thereof. The method comprises: subjecting starch and a fatty alcohol having a cycloalkane group to ultrahigh pressure treatment. Under ultrahigh pressure treatment, the starch and the cycloalkane group-containing fatty alcohol exhibit strong binding, effectively improving binding rate, crystallinity, and thermal stability. The resulting starch-fatty alcohol complex has a stable structure and high application value.

This invention belongs to the field of biotechnology, providing a mouse anti-human ELL2 monoclonal antibody, its preparation method, and its applications. This invention successfully obtained a 2E1 anti-human ELL2 monoclonal antibody and established a hybridoma cell line capable of stably producing this antibody. The binding affinity (KD) of the obtained 2E1 monoclonal antibody to human ELL2 protein reached the picomolar level (approximately 10^-3 kDa). ‑12 The antibody (M) exhibits extremely strong binding ability. Cross-reactivity tests confirmed that it binds only to human ELL2, and shows no binding signal with highly homologous human ELL1, ELL3, and mouse ELL2, thus completely solving the specificity problem of existing technologies.

A metal-chelating resin includes (a) a compound represented by Formula (I):or a stereoisomeric form thereof or a salt thereof, wherein R1, R2, R3, R4, Ra, Rb, Rc and Rd are as defined herein; and (b) an organic polymer resin having at least one complementary reactive functional group covalently linked with at least one linking group of the compound represented by Formula (I).

The application discloses a single-domain antibody against CD99 protein and a coding gene and application thereof. The single-domain antibody Nab99-30 against CD99 protein comprises three complementarity determining regions CDR1, CDR2 and CDR3, characterized in that the amino acid sequences are sequentially shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3; the amino acid sequence of the single-domain antibody Nab99-30 is shown in SEQ ID NO. 4, and the nucleotide sequence of the coding gene is shown in SEQ ID NO. 5. The single-domain antibody against CD99 protein screened by the application has the advantages of small volume, good stability, high activity and the like compared to common monoclonal antibodies, has strong binding capacity with CD99 protein, has high specificity and high affinity, and can be applied to preparation of a reagent for detecting CD99 protein or treatment of tumors with extracellular abnormal expression of CD99.

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The application relates to a G-quadruplex RNA fluorescent ligand and a preparation method and application thereof, a structure formula of the G-quadruplex RNA fluorescent ligand is shown in the following formula: the compound can be specifically targeted and can be subjected to fluorescent imaging in a solution system and a cell system, a high-throughput fluorescent screening method is established in the solution and the cell system, and an organic small-molecule compound with strong binding capacity to G-quadruplex RNA can be effectively identified and screened from a small-molecule drug library; the screening result of the method is high in accuracy, the affinity and biological activity of a candidate compound can be quickly determined by evaluating the change of a fluorescent signal, and therefore the research and development process of an antitumor drug is accelerated; and the application belongs to the field of biological medicines.

The embodiment of the invention discloses a vehicle control method and device, equipment and a storage medium, and belongs to the technical field of vehicle control. The method comprises the steps that a first vehicle path is obtained with a current path point of a first vehicle as a starting point; determining a first blocked vehicle set of the first vehicle based on the first vehicle path in combination with a waypoint binding relationship; the waypoint binding relation comprises a strong binding relation and a weak binding relation, the strong binding relation is used for indicating the relation between waypoints contained in the area where the vehicles are not allowed to be parallel, and the weak binding relation is used for indicating the relation between waypoints contained in the area where the at least two vehicles are allowed to be parallel; and sending first movement information to the first vehicle under the condition of determining that the first vehicle can reach the first waypoint based on the first blocked vehicle set. According to the method, the path planning pressure for the first vehicle is reduced, the blocking problem is predicted in advance, existence of the problem is predicted before the problem is generated, the blocking problem can be solved in time subsequently, and the smoothness of the driving process of the first vehicle is improved.

The invention discloses a decentralized identity strong binding and security recovery method. The method comprises the following steps: S1, deploying an intelligent contract on a block chain network; s2, a user generates a main public and private key pair through a smart contract, the smart contract allocates a unique decentralized identifier to a main public key, sets the main public key to be in an unverified state, and stores an association relationship between the decentralized identifier and the main public key; and S3, for the decentralized identifier in the unverified state, the user submits a binding assertion to the smart contract for validity verification, and after verification is passed, the decentralized identifier is converted into a verified state and granted with authority. The invention also discloses a decentralized identity strong binding and security recovery system. According to the method, the intelligent contract can realize operation of corresponding functions, intervention of a centralized mechanism is not needed in the whole process, the autonomous controllable characteristic of decentralized identity is reserved, and unification of safety, credibility and usability is realized through multi-party authoritative endorsement and a strict verification mechanism.

The application discloses a static self-assembly preparation method of a high-nickel ternary material nano-barium titanate core-shell structure. The technology realizes uniform coating of nano-particles on the surface of a base through electrostatic attraction by means of surface charge regulation and layer-by-layer self-assembly mechanism, that is, by immersing positively charged high-nickel ternary material into negatively charged nano-barium titanate slurry liquid. The application can obtain core-shell materials with strong binding force and controllable structure. The process is simple in operation and low in energy consumption. The barium titanate coating layer based on the coordination of the physical barrier and electric field modulation dual mechanisms effectively improves the interface stability and the electrochemical kinetic performance.

The present invention relates to the fields of medicinal chemistry, radiopharmaceutical chemistry, and clinical nuclear medicine, and in particular to a compound targeting CDK4 / 6 and a radioactive tracer derived therefrom. The CDK4 / 6-targeting compound has the structures shown in the following formulas (I) and (II). The radioactive tracer provided by the present invention has strong binding affinity with CDK4 / 6, can accurately locate CDK4 / 6 in vivo, exhibits excellent in vivo targeting performance, and achieves tumor molecular imaging through nuclear medicine imaging. Formula (I); Formula (II).

The invention belongs to the technical field of nano antibodies, and provides a nano antibody OVA-3-23 for resisting chicken ovalbumin and application of the nano antibody OVA-3-23. The nano antibody OVA-3-23 for resisting the chicken ovalbumin has an amino acid sequence as shown in SEQ ID NO. 1. According to the prepared nano antibody OVA-3-23 for resisting the chicken ovalbumin, in the field of directional fixation, accurate anchoring of the chicken ovalbumin is achieved with high specificity, and the defects of impurity interference and fuzzy positioning in traditional fixation are overcome; in the field of immunodetection, high specificity and strong binding force guarantee the detection accuracy, colloidal gold, enzyme and other multi-component components are matched, and the chicken ovalbumin is efficiently identified from food on-site fast screening to laboratory fine detection; in the field of enrichment and purification, a high-purity product is efficiently separated from a complex sample. Especially, reliable support is provided for application scenes such as food detection, feed quality monitoring, immunology and vaccine development, and an efficient solution is provided for detection, research and quality control related to chicken ovalbumin.

The invention discloses a method for rapidly cleaning and transferring a wafer-level two-dimensional material without damage. According to the method, a covalent bond is formed and a stable and regular self-assembled monomolecular layer is constructed by utilizing a strong binding force between a modifier molecule and a growth substrate, and the monomolecular layer effectively reduces the surface energy of the growth substrate, so that the interaction force between the growth substrate and a two-dimensional material is remarkably weakened, and the performance of the two-dimensional material is improved. The material is more easily stripped from the growth substrate; secondly, according to the method, low-viscosity PDMS is selected as a transfer medium, the medium can provide proper adhesive force, and it is ensured that the two-dimensional material cannot fall off due to insufficient adhesive force in the transfer process and cannot be damaged or residues due to too high adhesive force; and after the transfer is completed, the low-viscosity PDMS is more easily stripped from the target substrate, so that residues, bubbles and defects are reduced, and the original electrical and optical characteristics of the two-dimensional material can be effectively maintained.

The application provides an anti-IGFBP5 nanobody and a preparation method, application and product thereof, and belongs to the technical field of biotechnology.The anti-IGFBP5 nanobody provided by the application contains a CDR region shown in SEQ ID NO:1-3, or one or more amino acid sequences with a sequence similarity of at least 90% with SEQ ID NO.1-3 respectively, the anti-IGFBP5 nanobody prepared by the application has strong binding capacity and can inhibit tumor cell growth.

The present application provides a camel-derived nanobody targeting the shared epitope of SARS-CoV-2 RBD and its receptor ACE2, which simultaneously binds to the key sites F486, Q493 and S494 of SARS-CoV-2 RBD. The present application screens the purified nanobody VHH5-05, which not only shows strong binding capacity to phages displaying wild-type SARS-CoV-2 RBD, but also shows certain binding capacity to phages of Beta mutant strain RBD and Delta mutant strain RBD.

The invention discloses a conjugate of phosphorylated Tau protein and magnetic beads as well as a preparation method and a kit of the conjugate, and relates to the technical field of immunoassay. The modified magnetic beads modified with azide groups and the modified anti-phosphorylated Tau protein antibody modified with DBCO groups are efficiently and directionally coupled in a click chemistry mode, and compared with a traditional physical adsorption or non-specific chemical coupling method, the method has the advantages of being high in coupling efficiency, high in binding stability, high in antibody activity retention rate and the like; compared with the prior art, the magnetic bead provided by the invention has the advantages that the capture efficiency and specificity of the magnetic bead on low-abundance p-Tau in blood can be obviously improved, the lower detection limit is as low as 0.3 pg / mL or below, excellent accuracy is shown in early AD diagnosis, subtle changes of p-Tau in the blood of an early AD patient can be accurately identified, and a reliable tool is provided for early screening, disease course monitoring and intervention effect evaluation of AD.

The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC (NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.

The utility model relates to the technical field of auxiliary treatment of knee osteoarthritis, and discloses a brace for auxiliary treatment of knee osteoarthritis, which comprises a knee joint protector and a rotating frame, and the left end and the right end of the knee joint protector are fixedly connected with fixing snap rings. By arranging the two binding belts, after a user wears the leg, the binding belts are matched to bind the position of the leg, and when the length positions of the legs of the user are different, the binding belts are pulled to drive the extending sliding rod to extend and slide in the fixing sleeve, so that the leg length position of the user is adjusted. The length of the device can be conveniently adjusted according to the leg length of a user, when the user wears the device for use, rehabilitation training of the user is easily affected due to the fact that the constraint feeling is high when the user just starts to wear the device, movement is inconvenient, bumping is generated, and the device is worthy of popularization and application. And after the protective base plate is mounted in the fixed clamping ring and the positioning groove, the phenomenon that the knees collide with table corners or objects with edges and corners is reduced.

The invention relates to a security system and method for strongly binding a program and a hardware identifier, and belongs to the technical field of software protection and equipment authentication. According to the invention, an'authorization certificate 'uniquely bound with specific equipment is generated through a scheme of'encrypting a hardware identifier by a secret key derived from the hardware identifier'. The credential cannot be correctly decrypted and verified on any other hardware. When a protected program and an authorization certificate thereof are completely copied to another non-authorized device, due to different local hardware identifications of a new device, a correct decryption key cannot be generated when a program verification preamble module of the new device performs self-inspection, so that decryption fails and program operation is forcibly stopped, and therefore, pirate behaviors are effectively prevented.

The present disclosure relates to a multi-element catalyst and a method for preparing the same. The multi-element catalyst of the present disclosure, wherein a noble metal and a transition metal form an intermetallic crystal structure and are supported on a carbon support with strong binding force, can exhibit excellent durability, stability, and catalytic activity.

The invention discloses a reverse wetting agent for improving the oil recovery rate and a preparation method and application thereof, and relates to the technical field of reverse wetting agents. Comprising the following components in parts by weight: 3-7 parts of olefin sulfonate, 2-5 parts of iso-tridecanol polyoxyethylene ether, 10-25 parts of a wetting reversal compound, 0.5-3 parts of isopropanol, 1-5 parts of triethanolamine and 60-70 parts of water. The preparation method comprises the following steps: adding olefin sulfonate, iso-tridecanol polyoxyethylene ether, isopropanol and triethanolamine into water, stirring and dissolving, then adding the wetting reversal compound, and continuously stirring and mixing uniformly, thereby obtaining the water-based cleaning agent. The wetting reversal component in the petroleum wetting reversal agent prepared by the invention has strong bonding force with rock, so that the wettability of the rock surface is maintained for a long time, and the recovery rate of petroleum is improved.

The invention belongs to the technical field of biology, and discloses an anti-human AXL antibody, a gene and application of the anti-human AXL antibody, and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-human AXL antibody are respectively shown as SEQ ID NO.23-34. The anti-human AXL antibodies in some examples have the binding capacity EC50 value smaller than 2 nM for AXL antigens and have no binding capacity for irrelevant antigens Her2 and BSA, and it is indicated that the screened targeted AXL antibodies have high specificity and high binding activity. Different AXL / CD3 bispecific antibodies prepared on the basis of the anti-human AXL antibody have relatively strong killing ability (IC50: 0.1-0.5 nM) on AXL positive MDA-MB-231 cells, and have very low killing ability on AXL negative SKBR3 cells, so that off-target toxicity of the different AXL / CD3 antibodies is avoided, and the application of the different AXL / CD3 bispecific antibodies is further widened.

The invention discloses a quaternary quantum dot ZnCuInSe / CuInSe as well as a preparation method and application thereof, and belongs to the technical field of nano materials, the quaternary quantum dot ZCISe / CISe is prepared by adopting an aqueous phase method, and the quaternary quantum dot has good water solubility, stability and low toxicity, and has relatively long fluorescence lifetime compared with ZnCuInSe. The fluorescent property of the quantum dot can be enhanced by adsorbing Zn < 2 + > to the surface of the quaternary quantum dot ZCISe / CISe, and the fluorescence of the quaternary quantum dot is quenched due to the fact that the binding force between CQ and Zn < 2 + > is high and CQ can competitively capture Zn < 2 + > on the surface of the quaternary quantum dot ZCISe / CISe. Therefore, a fluorescent probe is constructed based on the prepared quaternary quantum dot ZCISe / CISe, sensitive detection of the cloidoquine can be realized, and the detection limit is 3.33 mu M.

The application discloses an antibody against human CD180 and application thereof. The antibody against human CD180 A24C9 and C12F11 provided by the application has strong affinity with human CD180 protein, and the Kd values are 0.4748 nM and 78.19 nM respectively; meanwhile, the antibody has strong binding specificity and can specifically recognize human CD180 positive acute myeloid leukemia (AML) cell lines (OCI-AML2, MV4-11, THP1) and human CD180 positive B cell lymphoma cell lines (Daudi, BJAB, Nalm6); and the antibody has no cross reaction with various human CD180 negative cell lines (K562, NB4, Kasumi1, TF1, NK92, Jurkat, SupT1 and MM1S). The antibody can be used for detecting expression of human CD180 protein, and can be used in immunotherapy alone or in combination with other methods, and has diagnostic and therapeutic values in tumors, autoimmune diseases, graft-versus-host diseases and inflammatory diseases.